Suomi - suomi - Fimea (Suomen lääkevirasto)

medical valley invest ab - rosuvastatin calcium - tabletti, kalvopäällysteinen - 40 mg - rosuvastatiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

life medical aps - sodium valproate - injektio-/infuusioneste, liuos - 100 mg/ml - valproiinihappo

Suomi - suomi - Fimea (Suomen lääkevirasto)

evolan pharma ab - adenosine - injektio-/infuusioneste, liuos - 5 mg/ml - adenosiini

Euroopan unioni - suomi - EMA (European Medicines Agency)

mabxience research sl - bevasitsumabi - colorectal neoplasms; breast neoplasms; ovarian neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiset aineet - alymsys in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. alymsys in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. alymsys in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with alymsys in combination with capecitabine. alymsys, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. alymsys, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations. alymsys in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. alymsys, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer. alymsys, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. alymsys, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm oy - ethinylestradiol, drospirenone - tabletti, kalvopäällysteinen - 0.03 mg / 3 mg - drospirenoni ja etinyyliestradioli

Euroopan unioni - suomi - EMA (European Medicines Agency)

itm medical isotopes gmbh - lutetium (177lu) chloride - radionuklidien kuvantaminen - terapeuttiset radiofarmaseuttiset valmisteet - endolusiinibeta on radiofarmaseuttinen prekursori, eikä sitä ole tarkoitettu suoraan potilaille. sitä on tarkoitus käyttää vain sellaisten kantajamolekyylien radioaktiiviseen merkintään, jotka on erityisesti kehitetty ja sallittu radiolabeloitavaksi lutetium (177lu) -kloridilla.

Euroopan unioni - suomi - EMA (European Medicines Agency)

corza medical gmbh - ihmisen fibrinogeeni, ihmisen trombiini - hemostaasi, kirurginen - hemostaatit - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Suomi - suomi - Fimea (Suomen lääkevirasto)

fresenius medical care deutschland gmbh - magnesium chloride hexahydrate, sodium hydrogen carbonate, glucose monohydrate, sodium chloride, calcium chloride - peritoneaalidialyysineste - hypertoniset liuokset

Suomi - suomi - Fimea (Suomen lääkevirasto)

fresenius medical care deutschland gmbh - sodium hydrogen carbonate, magnesium chloride hexahydrate, glucose monohydrate, sodium chloride, calcium chloride - peritoneaalidialyysineste - hypertoniset liuokset

Suomi - suomi - Fimea (Suomen lääkevirasto)

fresenius medical care deutschland gmbh - magnesium chloride hexahydrate, sodium hydrogen carbonate, glucose monohydrate, sodium chloride, calcium chloride - peritoneaalidialyysineste - hypertoniset liuokset